Actionable Answers for Tailored Treatment
Oncology testing is rapidly advancing—from new technology and discoveries in molecular biomarkers to emerging therapies. Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.
Guiding Treatment Selection
Lung cancer treatment options are selected based on molecular test results, and proper treatment selection directly impacts patient outcomes. Selecting the most appropriate treatment, whether standard, off-label, or clinical trials, begins with high-quality molecular testing.
More Results for More Patients
Accurate results are the first step to timely, effective, and efficient patient care. Unlike other laboratories, our specimen requirements are optimized to conserve tissue, which makes results available for more patients.
Expert Interpretation of Results
Your results are interpreted by Mayo Clinic physicians with expertise in pulmonary oncology. Each report integrates patient information with supporting references. This provides patient-specific context and a better understanding of the treatment path ahead.
Providing Results for More Patients
Lung cancer specimens are small and can vary in tumor content. Obtaining enough tissue for multiple molecular and histological tests has historically created a significant challenge for pathologists in testing patients for clinically actionable mutations as recommended.
Our lung cancer-specific NGS panel includes only clinically relevant markers allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of FFPE tissue and accepting cytology as an alternative specimen type, which allows more patients to receive results.
Finding the Right Cancer Treatment for Each Patient
Therapy selection in lung cancer patients is critical to acheiving the best outcomes. Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information can also be useful in prognosis.
Resistance Mutation Testing
Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.
Immunotherapies have recently emerged as a therapeutic option for patients with NSCLC. Therapies have been approved for both first and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression. Mayo Clinic Laboratories offers three PD-L1 clones for assessing patient response to specific therapies.